Solarase™

• Topical HA - diclofenac gel

• Treats actinic keratosis

  • Pre-cancerous skin condition
  • Affects 25% of adult population
  • Current U.S. market - $240 million

• Pending FDA approval

• Approved in several European countries and Canada

Previous slide

Next slide

Back to first slide

View graphic version